ADMA - NASDAQ
ADMA Biologics, Inc.
$7.93
+2.3%ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. The company also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
At a Glance
Live Snapshotadma
Total Stockholders' Equity
Last Annual Value
477.32M
3-Year CAGR
46%
5-Year CAGR
40%
10-Year CAGR
89%
ADMA Biologics, Inc. Competitors Analysis of Total Stockholders' Equity
| Company | Total Stockholders' Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
ADMA Biologics, Inc. NASDAQ:ADMA | 477.32M | 52.3% | 27.6% | N/A | |
 Crinetics Pharmaceuticals, Inc. NASDAQ:CRNX | 992.08M | 22.5% | 24.5% | N/A | |
 ACADIA Pharmaceuticals Inc. NASDAQ:ACAD | 1.23B | 41.7% | 17.8% | 9.0% | |
 Belite Bio, Inc NASDAQ:BLTE | 770.49M | 104.2% | N/A | N/A | |
 Dyne Therapeutics, Inc. NASDAQ:DYN | 972.13M | 120.0% | 21.4% | -7.2% | |
 Ligand Pharmaceuticals Incorporated NASDAQ:LGND | 1.02B | 13.2% | 4.4% | 10.6% | |
 Ultragenyx Pharmaceutical Inc. NASDAQ:RARE | -80.00M | N/A | N/A | N/A | |
 Mirum Pharmaceuticals, Inc. NASDAQ:MIRM | 314.69M | 8.2% | 21.2% | N/A | |
 Soleno Therapeutics, Inc. NASDAQ:SLNO | 450.12M | 41.9% | 90.8% | 62.8% | |
 Praxis Precision Medicines, Inc. NASDAQ:PRAX | 878.14M | 132.7% | 28.5% | N/A |
ADMA Biologics, Inc. Fair Value Envelope
Related Guides
Continue your ADMA research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.